

Date and time: Friday 15 May 2015, 1000-1600

Minutes: Confirmed

Guideline Development Group Meeting 8 **Non-alcoholic fatty liver disease (NAFLD)**

Place: Boardroom, NCGC, 180 Great Portland Street, London W1W 5QZ

Present: Christopher Byrne, Professor of Endocrinology & Metabolism, University of Southampton
 Chris Day, GDG Chair, Professor of Liver Medicine & Honorary Consultant Hepatologist, Newcastle University
 David Fitzmaurice, Professor of Primary Care, University of Birmingham
 Irene McGill, Patient/carer representative
 Benjamin Mullish, ST in Hepatology & Gastroenterology, Imperial College London (Specialist Trainee Adviser)
 Philip Newsome, Professor of Experimental Hepatology & Honorary Consultant Hepatologist, Birmingham University (did not formally participate in item 4 but remained present to answer direct questions of fact from the Chair)
 Tanja Pardela, Paediatric Liver Modern Matron, King's College Hospital
 Rachel Pryke, General Practitioner Partner, Winyates Health Centre, Redditch
 Jane Putsey, Patient/carer representative
 Indra van Mourik, Consultant Paediatric Hepatologist & Clinical Lead Liver Unit, Birmingham Children's Hospital NHS Foundation Trust
 Bronwen Williams, Gastroenterology and Hepatology Research Nurse, Hull Royal Infirmary
 Nick Hicks, Consultant in Public Health Medicine, Consultant Advisor HTA & EME Programmes (items 1-3 only)
 Pamela Young, Scientific Adviser (Identification) (items 1-3 only)
 Kate Ashmore, Document Editor/Process Assistant, NCGC (notes)
 Serena Carville, Associate Director, NCGC
 Leteris Floros, Health Economist, NCGC (item 7 onwards)
 Jessica Glen, Senior Research Fellow, NCGC
 Martin Harker, Senior Health Economist, NCGC
 Joshua Ruegger, Research Fellow, NCGC (item 5 onwards)
 Amelia Unsworth, Project Manager, NCGC

Apologies: Kevin Moore, Professor of Hepatology, University College London
 Qudsia Malik, Senior Research Fellow, NCGC

In attendance:

NICE Staff:	Louise Shires, Guidelines Commissioning Manager (items 1-6 only)	
-------------	--	--

Observers:

--	--	--

Notes**1. Welcome, apologies and declarations of interest**

The Chair welcomed the group to the eighth meeting of the non-alcoholic fatty liver disease (NAFLD) GDG. NH and PY, NETSCC advisers, attended to provide advice on NIHR funding opportunities and feedback on the NAFLD draft research recommendations.

Apologies were received from KM.

The Chair reviewed the declarations of interest (DOI) register and noted that, due to previously declared specific non-personal pecuniary interests, PN has a conflict of interest with the evidence review on pharmacological interventions. PN did not formally participate in this discussion but remained present to answer direct questions of fact on the Chair's request.

The Chair requested updates to the GDG members' existing DOIs. BW declared that on 1 May 2015 the Hepatology Research Team at the Hull Royal Infirmary received funding from the Health Foundation: Innovating for Improvement programme for a primary/ secondary care ICP project looking at diagnosis, referral and e-consult clinics for NAFLD. There will be an element of operational research to be conducted alongside the project which is currently being developed, but will focus on effectiveness of the NAFLD ICP model to support GPs in primary care and NAFLD patient outcomes. BW will be the project manager/advisor for this project. This was classified as a non-specific non-personal pecuniary interest. The Chair agreed that no action was required.

2. GDG7 minutes

The minutes of the last meeting were agreed as a true and accurate record.

3. Research recommendations

The GDG was given a presentation on the funding opportunities provided by NIHR and feedback on the draft research recommendations.

4. Evidence review: Pharmacological interventions

PN did not formally participate in this item but remained present to answer direct questions of fact on the Chair's request.

The GDG was given a presentation on the clinical and economic evidence for pharmacological interventions.

5. Evidence review: Alcohol advice

The GDG was given a presentation on the clinical and economic evidence on alcohol advice.

6. Evidence review: Fructose advice

The GDG was given a presentation on the clinical and economic evidence on fructose advice.

Notes

7. **Health economic model: update**

The GDG was given a presentation on the health economic model update.

8. **Any other business**

None.

Date, time and venue of the next meeting

GDG9: Friday 19 June 2015, 1000-1600, Boardroom, NCGC, 180 Great Portland Street, London W1W 5QZ.